By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Otsuka Pharmaceutical Co., Ltd. 

2-9 Kanda Tsukasa-cho
Tokyo    101-8535  Japan
Phone: 03-3292-0021 Fax:



Company News
Otsuka Pharma Release: 48-Week Data, Presented At The Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit With Adacolumn In A Sub-Group Of Refractory Patients With Ulcerative Colitis 5/23/2016 11:04:56 AM
FDA Spurns Otsuka Pharma, Proteus Digital Health's Drug/Device Combo 4/27/2016 6:03:36 AM
Otsuka Pharma Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment To Medimetriks Pharmaceuticals, Inc. 2/9/2016 5:54:19 AM
Ariad (ARIA) And Otsuka Pharma Submit New Drug Application In Japan For Ponatinib 1/8/2016 12:01:17 PM
U.S. FDA Accepts First Digital Medicine New Drug Application For Otsuka Pharma And Proteus Digital Health, Inc. 9/10/2015 10:17:19 AM
Efficacy Results Of Otsuka Pharma’s Delamanid (Deltyba) For Extensively Drug-Resistant Tuberculosis (XDR-TB) Published In The New England Journal of Medicine 7/16/2015 11:12:48 AM
Otsuka Pharma, H. Lundbeck A/S (LUN.CO) Beat Competitors With FDA Approval of Schizophrenia Drug 7/13/2015 6:38:10 AM
Otsuka Pharmaceutical Co., Ltd.’s JINARC The First-Ever Treatment Approved In Europe For Adults Living With ADPKD, A Chronic Genetic Kidney Disease 5/27/2015 10:57:58 AM
Otsuka Pharmaceutical Co., Ltd. Release: Pre-Filled Dual-Chamber Syringe For Abilify Maintena (Aripiprazole) Prolonged-Release Suspension For Injection, Used In The Treatment Of Schizophrenia, Receives Positive CHMP Opinion (Approval In EU) 3/30/2015 12:59:23 PM
Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease 3/2/2015 6:59:19 AM